LoginSignup
TLX

Telix Pharms Stock

StockStock
ISIN: AU000000TLX2
Ticker: TLX
AU000000TLX2
TLX

Price

Frequently asked questions

What is Telix Pharms's market capitalization?

The market capitalization of Telix Pharms is $4.59B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Telix Pharms's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Telix Pharms is 139.81. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Telix Pharms?

Telix Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.0982. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Telix Pharms's stock?

Currently, 7 analysts cover Telix Pharms's stock, with a consensus target price of $12.39. Analyst ratings provide insights into the stock's expected performance.

What is Telix Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Telix Pharms reported a revenue of $423.53M.

What is the EBITDA for Telix Pharms?

Telix Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $53.08M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Telix Pharms?

Telix Pharms has a free cash flow of $13.97M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Telix Pharms's stock?

The 5-year beta for Telix Pharms is 2.26. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Telix Pharms have, and what sector and industry does it belong to?

Telix Pharms employs approximately 234 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Telix Pharms's shares?

The free float of Telix Pharms is 248.16M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $4.59B

5Y beta

 2.26

EPS (TTM)

 $0.0982

Free Float

 248.16M

P/E ratio (TTM)

 139.81

Revenue (TTM)

 $423.53M

EBITDA (TTM)

 $53.08M

Free Cashflow (TTM)

 $13.97M

Pricing

1D span
$14.05$14.07
52W span
$6.877$8.38

Analyst Ratings

The price target is $12.39 and the stock is covered by 7 analysts.

Buy

7

Hold

0

Sell

0

Information

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

234

Biotechnology & Drugs

Health Care

Identifier

ISIN

AU000000TLX2

Primary Ticker

TLX

Knockouts

Join the conversation
Sign upLogin